|
|
Acne: Asthma Drug Fails to Help Patients with Acne |
|
|
The asthma drug Zyflo fails to help patients with severe acne,
according to a mid-stage trial carried out by the company
Critical Therapeutics Inc. The drug, also known as zileuton, was
neither better at controlling the number of inflammatory lesions
than placebos under the company statistics.
Over the 12-week trial, patients treated with Zyflo had an
average reduction of 11.5 inflammatory lesions. That compared
with a reduction of 9.1 lesions in a group of other patients
taking placebos - far short of achieving statistical
significance.
Patients treated with placebo showed a reduction of 16.4 lesions
in the placebo group, but patients treated with Zyflo showed a
mean reduction in the total number of lesions of 25.3.
The company stated the medicine showed a trend of potential
benefit to some patients although the |
|
|
|
drug failed the primary
goal of the trial.
Linda Lennox, the company spokeswoman, told the company will
probably conduct a larger trial testing the medicine as an acne
treatment, using information gleaned from the small recent
"proof of concept" trial.
The company based in Lexington, Massachusetts, said that it is
continuing to analyze the data and is working with the
investigators to further interpret the results.
Zyflo blocks an inflammation-causing enzyme called 5
lipoxygenase (5-LO). It was approved by U.S. regulators in 1996
for treating asthma patients 12 years of age and older. At the
time, the drug was owned by Abbott Laboratories Inc., which sold
it for a number of years before licensing it to Critical
Therapeutics in late 2003.
Article written by Hector Milla, editor of |
|
Untitled Document
|
|
'Free' acne product prompts rash of complaintsVancouver Sun, Canada - Aug 27, 2008BC I Consumers say they are continuing to pay for their acne scar treatment even if they opt out of the program. The Better Business Bureau of Mainland BC ... |
|
|---|
| |
